Hypothesis / aims of study
Long-term post-prostatectomy urinary incontinence affects between 3-10% of all patients who have undergone a radical prostatectomy. This can either be urodynamically proven stress urinary incontinence (SUI), detrusor overactivity (DO), or mixed urinary incontinence (MUI). This can have a severe impact on a patient’s quality of life. The aim of the study was to evaluate the efficacy of intravesical Botulinum Toxin A (Botox) for patients with Post-Prostatectomy incontinence from Overactive Bladder (OAB).
Study design, materials and methods
A retrospective review of all patients at a Tertiary London University Hospital was conducted from January 2018 – December 2020. The type of urinary incontinence was confirmed on urodynamics. Demographics and symptom severity were collected. ICIQ-OAB questionnaires were filled in by the patients before and 3 months after their procedure. 24-hour pad usage was quantified before and after the procedure. PG-II scores were filled in after their procedure to assess patient satisfaction with their intervention. Patients were followed-up at 3-month post-procedure. Student T-tests were used to assess for significance.
Interpretation of results
There is higher patient satisfaction and more effective symptom control, from intravesical Botox, reported from patients with pure DO than from patients with DO and SUI (MUI) combined.